Mobocertinib (mesylate)

• Description :

  Mobocertinib (TAK-788) mesylate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib mesylate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib mesylate can be used in NSCLC research[1][2].

• Product Name Alternative :

  TAK-788 (mesylate) ; AP32788 (mesylate)

• UNSPSC :

  12352005

• Target :

  EGFR

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/mobocertinib-mesylate.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C.O=S(O)(C)=O

• Molecular Formula :

  C33H43N7O7S

• Molecular Weight :

  681.80

• References & Citations :

  [1]Gonzalvez F, et al. Mobocertinib (TAK-788) : A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Jul;11 (7) :1672-1687.|[2]Han H, et al. Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Res. 2021 Oct 15;81 (20) :5311-5324.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  EGFR/ErbB1/HER1; ErbB2/HER2

• CAS Number :

  [2389149-85-1]